Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 02, 2022

SELL
$4.21 - $7.61 $51,703 - $93,458
-12,281 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$7.45 - $13.66 $91,493 - $167,758
12,281 New
12,281 $92,000

Others Institutions Holding RZLT

About Rezolute, Inc.


  • Ticker RZLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,600
  • Market Cap $191M
  • Description
  • Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...
More about RZLT
Track This Portfolio

Track Oppenheimer & CO Inc Portfolio

Follow Oppenheimer & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.